Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis by Pirola, Carlos Jose et al.
Circulating microRNA signature in non-alcoholic fatty liver 
disease: from serum non-coding RNAs to liver histology and 
disease pathogenesis
Carlos J Pirola1, Tomas Fernández Gianotti1, Gustavo O Castaño2, Pablo Mallardi3, Julio 
San Martino3, María Mora Gonzalez Lopez Ledesma4, Diego Flichman4, Faridodin 
Mirshahi5, Arun J Sanyal5, and Silvia Sookoian2,6
1Department of Molecular Genetics and Biology of Complex Diseases, Institute of Medical 
Research A Lanari-IDIM, University of Buenos Aires-National Scientific and Technical Research 
Council (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
2Liver Unit, Medicine and Surgery Department, Hospital Abel Zubizarreta, Ciudad Autónoma de 
Buenos Aires, Argentina
3Pathology Department, Hospital Diego Thompson, San Martin, Buenos Aires, Argentina
4Department of Virology, School of Pharmacy and Biochemistry, University of Buenos Aires, 
Ciudad Autónoma de Buenos Aires, Argentina
5Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia 
Commonwealth University School of Medicine, Richmond, Virginia, USA
6Department of Clinical and Molecular Hepatology, Institute of Medical Research A Lanari-IDIM, 
University of Buenos Aires- National Scientific and Technical Research Council (CONICET), 
Ciudad Autónoma de Buenos Aires, Argentina
Abstract
Objectives—We used a screening strategy of global serum microRNA (miRNA) profiling, 
followed by a second stage of independent replication and exploration of liver expression of 
selected miRNAs to study: (1) the circulating miRNA signature associated with non-alcoholic 
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fatty liver disease (NAFLD) progression and predictive power, (2) the role of miRNAs in disease 
biology and (3) the association between circulating miRNAs and features of the metabolic 
syndrome.
Methods—The study used a case-control design and included patients with NAFLD proven 
through biopsy and healthy controls.
Results—Among 84 circulating miRNAs analysed, miR-122, miR-192, miR-19a and miR-19b, 
miR-125b, and miR-375 were upregulated >2-fold (p<0.05) either in simple steatosis (SS) or non-
alcoholic steatohepatitis (NASH). The most dramatic and significant fold changes were observed 
in the serum levels of miR-122 (7.2-fold change in NASH vs controls and 3.1-fold change in 
NASH vs SS) and miR-192 (4.4-fold change in NASH vs controls); these results were replicated 
in the validation set. The majority of serum miR-122 circulate in argonaute2-free forms. 
Circulating miR-19a/b and miR-125b were correlated with biomarkers of atherosclerosis. Liver 
miR-122 expression was 10-fold (p<0.03) downregulated in NASH compared with SS and was 
preferentially expressed at the edge of lipid-laden hepatocytes. In vitro exploration showed that 
overexpression of miR-122 enhances alanine aminotransferase activity.
Conclusions—miR-122 plays a role of physiological significance in the biology of NAFLD; 
circulating miRNAs mirror the histological and molecular events occurring in the liver. NAFLD 
has a distinguishing circulating miRNA profile associated with a global dysmetabolic disease state 
and cardiovascular risk.
INTRODUCTION
MicroRNAs (miRNAs) are small (19–23 nucleotides) non-coding RNA molecules that 
regulate gene expression acting, at least in part, at a post-transcriptional level and fine-
tuning in concert the activity of thousands of genes and, consequently, their protein 
synthesis.1 Interestingly, miRNAs are stable in clinical samples because they are resistant to 
the action of ribonucleases; therefore, miRNAs detected in cell-free serum or plasma, also 
called circulating miRNAs, have been proposed as attractive diagnostic tools for 
distinguishing, non-invasively, diseased individuals from healthy ones.2 The scope of 
applications associated with miRNAs is even broader because they are used in different 
clinical settings for early disease detection and monitoring of disease progression and 
response to treatment for a wide range of disorders.
The increasing enthusiasm in the use of circulating miRNAs in clinical practice is explained 
by their ability to accurately reflect the physiological/pathological state of the tissue they are 
derived from. Thus, circulating miRNAs may be regarded as blood-based fingerprints of the 
affected tissue; therefore, they are powerful tools for the understanding of the disease 
biology. Finally, circulating miRNAs have a key role as signalling molecules because they 
are involved in cell-to-cell communication, supporting the idea that they might function as 
hormones.3–5 Consequently, miRNAs might be able to modulate cell phenotypes at distance 
from the cells they are derived from.
Non-alcoholic fatty liver disease (NAFLD) is a clinical condition that refers to potentially 
progressive histological changes ranging from fatty liver alone (simple steatosis (SS)) to 
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non-alcoholic steatohepatitis (NASH), a disease stage characterised by liver cell injury, 
mixed inflammatory lobular infiltrate and variable fibrosis.6
Although much research is being conducted to decipher the mechanisms associated with 
disease progression, many issues remain unsolved. For example, there is still missing 
information about the role of miRNAs in disease biology, and there is no reliable non-
invasive disease biomarker for distinguishing mild from severe histological disease stages.
In addition, whereas NAFLD has been implicated in metabolic syndrome (MetSyn)-
associated phenotypes, such as insulin resistance78 and cardiovascular disease (CVD), as 
reviewed recently,9 it is still unknown whether patients with NAFLD have a distinguishing 
circulating miRNA profile associated with a global dysmetabolic disease state and CVD 
risk. Hence, we investigated whether circulating miRNAs are able to reflect the 
physiopathological picture of the affected liver in patients with NAFLD, thus depicting a 
serum/plasma-based fingerprint of the fatty liver.
For this purpose, we used a screening strategy of global serum miRNA profiling, followed 
by a second stage of independent replication and exploration of liver expression of selected 
miRNAs to explore: (1) the circulating miRNA signature associated with NAFLD 
progression and the diagnostic performance of miRNAs in predicting liver histology, (2) the 
underlying pathophysiological mechanisms associated with the disease and (3) the 
association between differential expression of candidate miRNAs and features of the 
MetSyn.
The design was based on a case-control study and included patients with NAFLD proven 
through biopsy and healthy controls.
MATERIAL AND METHODS
Study design and selection of patients and controls
Human serum samples from healthy donors and patients with NAFLD, and liver biopsies 
from all the patients were obtained with written informed consent under Institutional Review 
Board-approved protocols (protocol number 104/HGAZ/09 and 89/100).
This study was done in three phases: (i) global serum miRNA profiling with a human serum 
and plasma miRNA PCR-based array, which profiles the expression of 84 miRNAs 
detectable and differentially expressed in serum and plasma; miRNAs were selected by the 
manufacturer based on previous knowledge about published association of the expression of 
miRNAs in serum and plasma in the context of either liver or heart injury, CVD or liver 
disease, cancer and miRNAs routinely present in normal serum (a complete list of the 
miRNAs included in the array is provided in the online supplementary material and online 
supplementary table S1) (MIHS-106Z, Qiagen, Chatsworth, California USA) (n=48 
participants). (ii) Independent validation of selected miRNAs based on their different 
patterns of expression and potential biological relevance to disease pathogenesis (n=96 
participants). (iii) Evaluation of liver expression of candidate miRNAs (n=65 participants, 
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51 NAFLD patients and the liver of 14 subjects without NAFLD (near-normal liver 
histology (NNLH).
Phases (i) and (ii) were conducted among independent groups of patients; phase (iii) 
involved liver tissue from patients recruited in phase (ii) and from patients with NNLH. 
Serum samples were collected by the time of liver biopsy in both cases and controls.
Patients were considered for inclusion at any study phase only if they had histopathological 
evidence of NAFLD, either SS or NASH, on liver biopsy done within the study period. 
Female and male patients with daily alcohol consumption of >20 and 30 g, respectively, 
were not included in the study.
Health examinations included anthropometric measurements, a questionnaire on health-
related behaviours, and biochemical determinations; measurements and blood sampling 
were obtained from each patient at the time of liver biopsy and before any intervention.
Specific biomarkers of inflammation (leucocyte count and C reactive protein) and 
atherogenesis (soluble intercellular adhesion molecule-1 (sICAM-1); plasminogen activator 
inhibitor-1 (PAI-1); soluble CD40 ligand; and resistin), and plasma caspase-generated 
cytokeratin-18 (CK-18) fragments were also measured.
Controls were selected from subjects whose age and sex matched those of the NAFLD 
patients. In addition to the standard health assessment described below, a careful 
ultrasonographic examination of the liver was done to exclude fatty liver infiltration. 
Controls were included at any study phase if they did not show features of MetSyn and did 
not have fatty liver at liver ultrasonography.
The reason for doing a liver biopsy in NNLH subjects was based on the presence of 
persistently mildly elevated serum liver enzyme activity. In all the NNLH subjects, all 
causes of common liver disease were ruled out, and these patients were included in the study 
if they did not present histological evidence of fatty change; the histological diagnosis was 
minimal changes or mild cholestasis.
ISH for localisation and quantification of liver miR-122
To localise and quantify candidate miRNAs in the liver, we performed in situ hybridisation 
(ISH) based on double digoxygenin-labelled locked nucleic acid oligos in formalin-fixed 
and paraffin-embedded tissue sections of NAFLD patients and controls.
Cell culture and transfection of synthetic miR-122 mimic and miR-122 inhibitor
To explore the effects of miR-122 on the regulation of liver enzymes, we used a 
LightSwitch MIM0136 hsa-miR-122-5p mimic, a chemically synthetic double-stranded 
RNA that acts as a functional equivalent of endogenous human miR-122, to transfect Huh-7 
hepatoma cells.
Complete details regarding physical, anthropometric, biochemical, and cardiovascular 
evaluation, statistical analysis, liver biopsy and histopathological evaluation, miRNA 
isolation and quantification by real-time quantitative reverse-transcription PCR (RT-PCR) 
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assay, immunoprecipitation of circulating miR-122 associated with argonaute2 (Ago2) 
complexes, liver immunohistochemistry (IHQ) and ISH, genotype analysis, pathway and 
target prediction, cell culture experiment, and a detailed summary study-flow chart are 
available in the online supplementary material.
RESULTS
Tables 1–3 show physical, anthropometric, biochemical and CVD evaluation, including 
biomarkers of atherosclerosis, of patients and controls in all the study phases.
Circulating miRNAs
Differential circulating miRNA profile of NAFLD patients: results of serum 
miRNA PCR-based array (discovery analysis)—To map the circulating miRNA 
expression profile in NAFLD, we first screened the serum of patients and controls by using 
a miRNA expression array. The heatmap diagram in figure 1 depicts a marked differential 
expression in several miRNAs in patients with SS and NASH when compared with controls; 
a heatmap of individual replicates is shown in the online supplementary material 
(supplementary figure S1). Among 84 miRNAs analysed, serum miR-122, miR-192, 
miR-19a and miR-19b, miR-125, and miR-375 were upregulated >2-fold (p<0.05) either in 
SS or NASH (figure 1). The most dramatic and significant fold changes were observed in 
the levels of miR-122 (7.2-fold change in NASH vs controls and 3.1-fold change in NASH 
vs SS) and miR-192 (4.4-fold change in NASH vs controls) (figure 1).
Validation of selected circulating miRNAs by RT-PCR (confirmation analysis)
Its role in the stratification of histological disease severity: We selected the six above-
mentioned significantly overexpressed miRNAs (see online supplementary table S2 for 
primers sequence) for validation in an independent and larger sample of well-characterised 
patients and controls. Regression analysis for an ordinal multinomial distribution showed 
that miR-122, miR-192 and miR-375 were significantly associated with the histological 
disease severity and significantly upregulated in NASH compared with SS patients 
(p=0.006, p=0.03 and p=0.04, respectively, in a non-parametric Mann–Whitney U test 
(figure 2). There were no gender differences in circulating miRNAs profiles and disease 
severity (ordinal multinomial probit, Wald statistic 0.13, p: 0.70).
We further explored the association between the expression level of these miRNAs and the 
individual components of the NAS in all the NAFLD patients (n=77). Of note, by grouping 
the dependant variable according to NAS severity, hepatocellular ballooning, degree of liver 
fat infiltration, lobular inflammation and liver fibrosis, we observed a significant association 
between the serum levels of miR-122, miR-192 and miR-375 and both the NAS and cellular 
ballooning (figure 2). However, only the serum levels of miR-122 were significantly 
associated with the presence of advanced fibrosis by grouping fibrosis stage as 0–1 versus 
2–3 (figure 2).
Although the degree of steatosis was higher in the NASH group compared with SS patients, 
the serum levels of the explored miRNAs were not significantly associated with fatty liver 
infiltration (mild ≤33% vs moderate or severe >33%; see online supplementary figure 1). In 
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addition, lobular inflammation was not associated with the circulating levels of the 
examined miRNAs (see online supplementary figure 1). Finally, a significant and strong 
correlation between miR-122 and liver enzymes was observed (table 4).
Receiver operating characteristic (ROC) curves were obtained to evaluate the performance 
of these miRNAs in predicting histological features associated with disease severity. The 
accuracies of miR-122, miR-192 and miR-375 to discriminate an advanced disease from a 
mild clinical form were fair and quite similar to each other (figure 2), showing on average an 
area under the ROC (AUROC) curve of about 0.7.
Furthermore, ROC analysis was adjusted by body mass index (BMI), and the results were 
similar to the unadjusted ones (see online supplementary material supplementary figure S2).
We also explored classic biomarkers used in the clinical setting to predict the presence of 
advanced liver disease, for example, a marker of cellular apoptosis (CK-18) and liver 
transaminases (alanine and aspartate aminotransaminases (ALT and AST). Figure 3 shows 
the overall performance of these biomarkers compared with miR-122 in predicting NASH 
and fibrosis in our population. Of note, miR-122 did much better than CK-18 and slightly 
better than ALT or AST in distinguishing patients with NASH and in predicting liver 
fibrosis (figure 3). Interestingly, and not totally unexpected, we observed that miR-122 and 
miR-192 were significantly and positively correlated with serum CK-18 levels (R=0.4, 
p<0.03 and R=0.37, p<0.03, respectively).
Finally, we performed multivariate ROC analysis and observed that the incorporation of 
multiple biomarkers into the model did not perform better to predict the disease severity, and 
miR-122 is as good as transaminases in discriminating a NAS score above 5 (see online 
supplementary material, online supplementary figures S3–S4 and online supplementary 
table S5).
Circulating miRNAs and its relationship with features of the MetSyn: Next, we 
attempted to confirm the differential expression observed for miR-19a and miR-19b and for 
miR-125b, which was significantly associated with NAFLD in the screening phase; miR-19a 
and mir-19b belong to the same cluster of miRNAs located in Chr13 (see online 
supplementary figure 2). In the replication stage, these miRNAs were significantly higher in 
SS and NASH compared with controls, but they did not differ between SS and NASH (see 
online supplementary figure 2). Nevertheless, these miRNAs were significantly associated 
with features of the MetSyn (fasting plasma glucose, triglyceride levels and BMI) and 
biomarkers of CVD risk and atherogenesis (sICAM-1 and PAI-1 levels) (table 4). miR19a/b 
and miR-125b were also involved in disease pathways associated with metabolic disorders, 
regulation of blood pressure and blood coagulation, including formation of thrombin (see 
online supplementary material and online supplementary table S6).
Role of Ago2-ribonucleoprotein complexes in the release of miR-122 into the 
circulation in patients with NAFLD—Argonaute proteins are the direct binding 
partners of small RNAs, and human Ago2 is associated with the catalytic activity required 
for mRNA cleavage.10 Of note, a previous study found that miRNAs, including miR-122, 
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circulate in plasma/serum in vesicle-free ribonucleoprotein complexes, in association with 
Ago2.11 Moreover, it was proposed that miR-122 is released through a protein carrier 
pathway because it was only detected in protein-associated fractions.12
Thus, to explore whether circulating miR-122 in NAFLD patients is primarily exported in 
association with Ago2 protein, we quantified its expression in Ago2-linked and Ago2-free 
fractions in circulation.
We showed that the relative abundance of circulating miR-122 in NAFLD patients was 
higher in the Ago2-free supernatant compared with the amount that immunoprecipi-tated 
with the anti-Ago2 antibody; patients with NASH and SS showed a significant enrichment 
(>10-fold and sevenfold, respectively) of free miR-122 in the circulation compared with that 
in association with Ago2 complexes (figure 4). Nevertheless, a small fraction (around 25%) 
of miR-122 circulates in serum in association with Ago2; this maintains the same pattern of 
higher levels in NASH observed in the Ago2-free pool. Of note, the Ago2 complexes are 
several-fold enriched in miR-122 with respect to miR-23a; after normalisation, the ratio of 
miR-122 in the immunoprecipitate/supernatant is completely reversed (data not shown).
To explore the source of circulating miR-122-Ago2 complexes, we further evaluated by IHQ 
the expression of Ago2 protein in liver tissue of NAFLD patients with different degrees of 
histological severity and in the liver of NNLH subjects. Ago2 was barely expressed in 
controls; the immunoreactivity product of Ago2 in NAFLD was confined to the cytoplasm 
of hepatocytes, primarily but not exclusively restricted to areas loaded with lipids (figure 4). 
In addition, Ago2 was expressed at the edge of the wall of hepatocytes. The staining scores 
according to the disease status showed that the liver expression of Ago2 had the same 
pattern as that of miR-122 observed by ISH, which was significantly higher in patients with 
SS compared with NASH patients (figure 4). In summary, we may suggest that miR-122 and 
Ago2 are colocalised in the hepatocyte and that serum miR-122 in Ago2-free and Ago2 
complexes may have the same origin.
Genetic variation of a validated miR-122 target gene: a candidate-gene association study
miR-122-related sequence genetic variation in the 3′UTR of the L-arginine 
transporter gene (SLC7A1) is associated with arterial hypertension—A 
functional variant within the 3′-untranslated region (UTR) of the SLC7A1 gene (rs41318021 
C/T, formerly submitted as ss52051826) was previously associated with essential 
hypertension.13 The results of experimental models showed that changes in the expression 
of SLC7A1 were associated with changes in nitric oxide production leading to endothelial 
dysfunction.13 The rs41318021 variant is associated with a miR-122 binding site that is 
involved in controlling SLC7A1 gene expression.14
Hence, to explore the hypothesis of a putative relationship among miR-122, the rs41318021 
variant and features of the MetSyn, we included 248 individuals (100 subjects without fatty 
liver and 148 NAFLD patients) in the analysis; details are given in the online supplementary 
material. Case-control association analysis of rs4131802 was done through logistic analysis. 
The genotype distribution was in Hardy–Weinberg equilibrium.
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Interestingly, we found that the rs41318021 variant was significantly associated with arterial 
systolic/diastolic hypertension (Pearson χ2: 7.85, p<0.019); the distribution of genotypes 
according to disease trait is provided in the online supplementary material (supplementary 
table S4). In the dominant model, the OR for arterial hypertension (OR, 5.01; 95% CI 1.79 
to 14.00; p<0.003) or isolated diastolic hypertension (OR, 4.54; 95% CI 1.49 to 13.87; 
p<0.008) was still significant even after adjusting for age, BMI and fatty liver. These 
findings suggest that the 3′UTR variant in human SLC7A1 may increase susceptibility to 
arterial hypertension in patients with NAFLD by interacting with miR-122, which is 
significantly upregulated in circulation, as previously shown. Remarkably, the expression 
levels of miR-122 in liver, which feed the higher levels in circulation, significantly and 
negatively correlate with systolic arterial blood pressure (R=−0.46, p<0.01).
Liver expression of candidate miRNAs
Expression pattern of liver miR-122 in NAFLD patients according to disease 
severity and tissue localisation—To explore the pattern of liver miR-122 expression 
and its relationship with the histological disease severity, we quantified the miR-122 
expression levels in NAFLD compared with NNLH patients. Surprisingly, NASH patients 
showed a systematic downregulation in the liver expression of those miRNAs that were 
upregulated in serum, for instance, miR-122 and miR-192 (figure 5). Of note, the liver 
expression of miR-122 and miR-192 was 10-fold (p<0.03) and almost twofold (p<0.03) 
downregulated, respectively, in NASH patients compared with SS (figure 5); the liver 
expressions of miR-122 and miR-192 were significantly correlated (R=0.56, p=0.00004).
In addition, we used ISH to study the distribution of liver miR-122 and putatively 
understand its release into the circulation and to validate the results of qPCR expression. We 
con-firmed that miR-122 is preferentially localised at the edge of lipid-laden hepatocytes 
being homogeneously distributed throughout the lobule without zone preferences but with 
high accentuation in areas of fat degeneration and zone 3.
In addition, we noticed that higher levels of miR-122 were expressed at the edge of the wall 
of hepatocytes rather than in the cytoplasm, suggesting that miR-122 is ready to be exported 
into the circulation (figure 5). Furthermore, we observed that NASH patients had 
significantly lower miR-122-hybridisation marks than did patients with SS (figure 5).
Finally, liver miR-122 expression was significantly and inversely correlated with central 
obesity (R=−0.40, p=0.03), serum low-density lipoprotein-cholesterol (R=−0.30, p=0.04) 
and serum alkaline phosphatase levels (R=−0.42, p=0.003).
In vitro studies to examine putative mechanistic pathways of the relationship between 
miR-122 and transaminases
miR-122 positively regulates alanine aminotransferase activity—The 
dysregulation of miR-122 expression is known to affect normal liver function and 
metabolism;15 thus, we hypothesised that miR-122 and liver transaminases (ALT or GPT 
and AST or GOT), which have as a common source the liver and which levels were 
significantly higher in the circulation in NAFLD, might share underlying regulatory 
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mechanisms. We performed an in vitro study in which we both overexpressed and blocked 
the endogenous miR-122 activity (details are provided in the online supplementary material) 
to explore putative changes in the liver transcriptional activity of aminotransferases genes 
(see online supplementary table S3 for primers sequence); toward this end, we transfected 
Huh7 cells with synthetic miR-122 mimic and its inhibitor.
We observed that the overexpression of miR-122 significantly enhanced ALT but not AST 
enzymatic activity in liver cell lysates (Kruskal–Wallis Test: p<0.02; figure 6). Interestingly, 
the GPT1 (the gene that encodes the cytosolic alanine aminotransaminase 1 (ALT1), GOT1 
(the gene that encodes the cytoplasmic form of glutamic-oxaloacetic transaminase, AST) 
and GOT2 (the gene that encodes the mitochondrial form of glutamic-oxaloacetic 
transaminase) mRNA levels did not change during either miR-122 overexpression or loss-
of-function experiments (figure 6). This novel finding suggests that miR-122 upregulates the 
translation of the ALT (GPT1) protein, leading to increased enzymatic activity. Although it 
is common knowledge that miRNAs usually repress gene transcription by degrading target 
mRNAs, induction of protein translation has been previously reported.16 Surprisingly, Ago2, 
which is highly expressed in NAFLD compared with control liver, is involved in the 
mechanisms that lead to translation activation by interacting with miRNA-responsive 
elements.16
In order to replicate our in vitro findings, we evaluated the expression of GPT1 mRNA in 
the liver of NAFLD patients, and similar to the observations in Huh7 cells, the expression 
levels of miR-122 and GPT1 mRNA were not significantly associated, suggesting that 
miR-122 does not influence liver GPT1 transcription.
Target prediction: miR-122 has predicted complementary sites located in the 
coding region of GPT1 mRNA—miRNAs usually repress gene expression by 
interfering with their target-mRNA gene by base pairing in the untranslated regions (3′-UTR 
and 5′-UTR) inducing mRNA destabilisation and translational inhibition; binding to the 5′-
UTR can either repress or activate translation. Consistent with our experimental results, in 
silico sequence analysis by five well-established programmes for miRNA and 3′-UTR-target 
interactions (TargetScan, PITA, miRanda, miRBase and PicTar) showed that GPT1 3′-UTR 
region has not predicted miR-122-target sites. Likewise, we used specific bioinformatics 
approaches for miRNA-target sites in 5′-UTRs (miRTar 2, Sfold-STarMirDB, 
MiRNA_Targets 2012 and Mircode) and observed that miR-122 does not target the GPT1 
5′-UTR region.
Previous observations demonstrated that coding sequence-located miRNA target sites are 
able to stimulate protein expression.17 Given that miR-122 upregulated in vitro the activity 
of GPT protein, we speculated that the binding interaction between miR-122 and GPT1 
might not reside in the UTR regions. Thus, we explored for putative miR-122 target sites on 
the whole GPT1 cDNA sequence by free energy-based miRNA prediction programmes 
(PITA and MicroInspector), and found six putative miR-122-target sites, including one 
located in position 137 with a high energy score, suggesting that miR-122 could possibly 
interact with GPT1 at multiple sites of the coding region (see online supplementary material 
and online supplementary table S7).
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In silico analysis of pathways associated with dysregulated miRNAs in NAFLD
Rather than exploring the putative hundreds of target genes associated with dysregulated 
miRNAs in NAFLD, we mapped the disease pathways in which these genes are involved 
(see online supplementary figure 3). The pathways associated with the MetSyn in which the 
miRNA-associated target genes are involved are provided in the online supplementary table 
S6. Of note, miR-19a/b and miR-125b are involved in biological processes that support their 
association with an altered CVD risk profile. In addition, the targets of the dysregulated 
miRNAs belong to a highly interacting network; interestingly, some targets were previously 
reported to have altered mRNA in NASH versus SS patients,18 including but not limited to, 
transforming growth factor-β1 (TGF-β1) (see online supplementary table S6).
DISCUSSION
This multiphase case-control study explored the role of circulating miRNAs in NAFLD 
patients at different stages of histological disease severity; we performed an initial step of 
global exploration of circulating miRNAs, followed by two steps of individual RTPCR 
evaluation, one in serum and another in liver tissue. In the training sera samples, we 
identified six miRNAs, including miR-122, miR-192, miR-375, miR-19a and miR-19b, and 
miR-125b, the concentrations of which were significantly upregulated in patients with 
NAFLD compared with healthy controls. ROC analysis in the validation samples revealed 
that three miRNAs, including miR-122, miR-192 and miR-375, have the potential to 
distinguish NASH from SS, but only miR-122 distinguishes liver fibrosis. We also 
compared the predictive value of serum miR-122 and classic disease biomarkers, including 
CK-18, ALT and AST, and we observed that miR-122 was slightly superior in predicting 
NASH and fibrosis in our population (AUROC 0.714). Although this predictive value is not 
good enough for an ideal biomarker, the performance of miR-122 is quite similar to that of 
CK-18 in predicting NASH (AUROC 0.65) and fibrosis (AUROC 0.68), as recently reported 
in a multicentre study.19 Consequently, there is no accurate non-invasive disease biomarker 
for distinguishing NASH from SS, and bio-marker discovery still remains a big challenge.
Interestingly, miR-122 and miR-192 significantly correlated with CK-18 levels, suggesting 
that they mirror a common pathophysiological condition, such as a caspase-related apoptosis 
pathway.
A remarkable finding to highlight is the putative role of circulating miR-122 as an 
extrahepatic fingerprint of NASH. For instance, in our study, the liver expression of 
miR-122 was significantly decreased in NASH, as previously shown by Cheung et al.20 In 
addition, the localisation of hybridisation marks showed a consistent pattern of miR-122 
expression at the edge of the wall of hepatocytes, suggesting that miR-122 is ready to be 
exported into the circulation. Overall, these findings suggest that the lower expression of 
miR-122 in liver is a consequence of a high rate of release into the circulation rather than a 
down-regulation of miRNA expression per se. In fact, the inverse relationship between 
circulating and tissue expression of miR-122 seems to be the consequence of a dynamic 
regulation of the biology of miR-122 in the liver. This phenomenon generates a dynamics of 
miR-122 production/release that reflects the behaviour of flux of substances/molecules 
between compartments. Accordingly, there are multiple reports, including a wide range of 
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diseases associated with liver injury (from acute viral hepatitis and drug-induced liver injury 
to liver cancer), that validated the opposite expression pattern of circulating and liver 
miR-122.21–23 Thus, collectively, these results indicate that the inverse relationship between 
tissue and circulating miR-122 may reflect a phenomenon of physiological significance in 
the biology of liver diseases, including NAFLD. Finally, it is hard to infer mechanisms from 
the analysis of the steady state levels of interconnected compartments, but as the final and 
largest reservoir may be the circulation, it is tempting to speculate that the overall 
production of miR-122 is increased in NAFLD.
In addition, serum miR-122 was significantly associated with hepatocellular ballooning, 
suggesting a putative role of this miRNA in the pathogenesis of NAFLD because this 
histological feature represents a morphological hallmark of NASH involving degenerative 
changes, a dilated endoplasmic reticulum and cytoskeletal injury.24 Hence, circulating 
miR-122 might be an interesting biomarker in monitoring the progression of histological 
changes, for instance, during therapeutic intervention. Furthermore, serum miR-122 levels 
were significantly associated with fibrosis scores, but liver miR-122 expression was not 
associated with either histological grading or staging. Notably, a recent in vitro study 
showed that miR-122 expression was downregulated in activated primary rat hepatic stellate 
cells (HSCs) suggesting a role of miR-122 in the regulation of collagen production.25 
Therefore, it might be interesting to explore in further studies the behaviour of miRNAs in 
HSCs from NASH patients to confirm whether these cells are able to express miR-122.
Circulating miR-122 has also been proposed as an early disease severity-dependent 
biomarker of liver injury (viral, alcohol and drug-related) because its levels become elevated 
earlier than that of serum ALT.2627 We observed that in NAFLD patients, miR-122 is 
strongly correlated with serum ALT; thus, to better understand this relationship, we explored 
in vitro the gene expression levels and the enzymatic activity of GPT1, GOT1 and GOT2, 
and ALT and AST, respectively, in Huh-7 hepatoma cells that either overexpress or have 
blocked miR-122. We uncovered a novel finding in that miR-122 played a regulatory role in 
the levels of ALT without changing the transcriptional levels of the coding gene. 
Surprisingly, over-expression of miR-122 caused a significant increase in ALT enzymatic 
activity compared with cells transfected with a scramble miRNA or a miR-122 inhibitor, 
suggesting that this miRNA is involved in translation activation of ALT. Our findings are 
supported by previous studies showing that miRNA–protein complexes oscillate between 
repression and activation; for instance, Vasudevan et al16 identified a miRNA (miR-369-3) 
that, in direct association with Ago2, is able to activate translation of its target gene. 
Similarly, Henke et al28 showed that miR-122 enhances the efficiency of HCV protein 
translation. In addition, target site prediction analysis using full-length cDNA sequence of 
GPT1 revealed at least six potential miR-122 target sites, which may interact cooperatively 
to enhance protein translation. Similar results of translation upre-gulation without altering 
mRNA levels were previously reported;29 moreover, the ENCODE Project demonstrated 
that miRNAs are able to bind multiple non-UTR sites in their target genes.30 Furthermore, 
although more experiments should be done, recent evidence showed that substantial fraction 
of human miRNA target sites are non-canonical.31
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The fact that ALT is involved in cellular nitrogen metabolism and in liver gluconeogenesis 
by catalysing the transamination between alanine and 2-oxoglutarate suggests a novel role of 
miR-122 in the modulation of glucose metabolism that has not been previously reported. 
Interestingly, the preferential localisation of miR-122 around lipid droplets of the 
hepatocytes reinforces this concept.
Contrary to the findings of Arroyo et al,11 we observed that extracellular Ago2-miR-122 
complexes represent a small fraction of the serum of NAFLD patients. As shown in 
experimental studies, miR-122 mostly circulates in Ago2-free complexes.26 Nevertheless, 
Ago2, a member of the argonaute protein family involved in the RNA-induced silencing 
complex, was found to play a role in the pathogenesis of NAFLD because its liver 
expression showed a significant upregulation that followed the same expression pattern as 
that of liver miR-122. Unfortunately, the limitations of our technique prevented us from 
proving colocalisation. However, we showed that circulating miR-122, either in other forms 
or in Ago2 complexes, seems to originate from the same cell type and reflects the same 
underlying disorder.
Another interesting finding of our study is the significant association of miR-192 and 
miR-375 with the disease severity. Indeed, the dysregulation of miR-192, which is 
upregulated by TGFβ1,32 and miR-375, which is a key regulator of glucose homeostasis and 
essential for adaptive β-cell expansion in response to increasing insulin demand in insulin 
resistance,33 confirms the importance of these miRNAs in the pathogenesis of NAFLD. In 
agreement with these findings, we previously observed in our population that the liver 
TGFβ1 expression was sevenfold increased in NASH compared with SS.18 Hence, miR-192 
is clearly a profibrogenic molecule involved in fibrosis development in many other tissues 
such as in kidney by activation of TGF-β/Smad signalling.34 Moreover, we hypothesise that 
the increased circulating miRNA levels may have some impact on the MetSyn phenotypes. 
Because miR-122 showed higher levels in circulation, we first looked at a functional 
polymorphism in the 3′UTR region of a validated miR-122 target gene (SLC7A1), the 
expression of which is affected by miRNA. We observed that rs41318021 was significantly 
associated with arterial hypertension, suggesting that miR-122 might potentially modulate 
the susceptibility to elevated blood pressure in subjects who carry the risk allele of this 
variant. Our results might suggest a scenario in which circulating levels of miR-122 might 
regulate the expression of genes involved in endothelial damage, for example, SLC7A1.514
Besides, among the dysregulated miRNAs in circulation, we identified a set of miRNAs that 
were unique to only the risk of CVD and atherogenesis in patients with NAFLD, such as 
miR-19a/b (associated with NF-κB signalling)35 and miR-125b (associated with 
inflammation).36 Interestingly, these miRNAs were upregulated in NAFLD patients without 
any relation to the disease severity, suggesting that the underlying systemic inflammatory 
state associated with fatty liver is irrespective of the histological status. Accordingly, in 
silico analysis of pathways under the miRNA-network regulation revealed that miR19b/a 
and miR-125b are critically involved in metabolic homeostasis, complement and coagulation 
cascades, glutathione metabolism, and the reninangiotensin system.
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Given that about 60% of all mammalian protein-encoding genes are regulated at post-
transcriptional level by miRNAs,37 any explanation by which the dysregulated miRNAs in 
our study modulate MetSyn might result in insufficiency. Nevertheless, accumulating 
evidence supports the metabolic and molecular mechanisms whereby miRNAs might 
potentially explain the association between fatty liver and MetSyn-associated diseases;38 for 
instance, the inflammation-associated miR-125b that is involved in vascular dysfunction and 
associated with increased oxidant stress and insulin resistance in diabetic mice,36 or the liver 
specific miR-122, which not only has a significant impact on lipid homeostasis3940 but is 
involved in cardiac fibrosis by modulating myocardial TGFβ1 expression.41 Furthermore, 
dysregulated cholesterol metabolism in NAFLD, which may contribute to disease severity 
and cardiovascular risks, is regulated by miRNAs.42
In conclusion, our results suggest that NAFLD has a distinct circulating miRNA signature, 
which is a reliable fingerprint of the morphological changes occurring in liver tissue. In 
addition, by characterising the dysregulated miRNAs in the circulation, we might be able to 
identify key signalling pathways involved in the pathogenesis of the disease and its 
relationship with the MetSyn; hence, miRNA profiling could also identify individuals at 
risk.
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Significance of this study
What is already known on this subject?
• MicroRNA (miRNAs) are small RNA molecules that participate in the post-
transcriptional fine tuning of gene regulation.
• Circulating miRNAs have been proposed as attractive diagnostic tools for 
distinguishing, non-invasively, diseased individuals from healthy ones.
What are the new findings?
• miR-122 (which constitutes more than 70% of the total liver miRNA pool), 
miR-192 (upregulated by TGFβ1) and miR-375 (a key regulator of glucose 
homeostasis) were significantly elevated in non-alcoholic steatohepatitis 
(NASH) compared with simple steatosis. NASH patients showed a systematic 
downregulation in the liver expression of those miRNAs that were upregulated 
in serum.
• We uncovered novel findings about miR-122 and the biology of non-alcoholic 
fatty liver disease (NAFLD): miR-122 mostly circulates in Ago2-free 
complexes and is expressed by the lipid-laden hepatocytes. In Huh7 cells, 
miR-122 regulates the levels of ALT without changing the transcriptional level 
of the coding gene, suggesting that it is involved in translation activation of 
ALT; miR-122 might interact with GPT1 (ALT) at multiple sites of the coding 
region to enhance translation. A functional variant (rs41318021) in the 3′UTR 
region of a validated miR-122 target gene involved in endothelial damage 
(SLC7A1) was significantly associated with arterial hypertension. The 
expression levels of liver miR-122 significantly and negatively correlated with 
systolic arterial blood pressure.
• NAFLD has a distinguishing circulating miRNA profile associated with a global 
dysmetabolic disease state and cardiovascular disease risk, such as miR-19a/b 
(associated with NF-κB signalling) and miR-125b (associated with 
inflammation).
How might it impact on clinical practice in the foreseeable future?
• The circulating miRNA signature of NAFLD mirrors the molecular events 
occurring in the liver and provides clues for the understanding of the disease 
biology.
• The application in the clinical setting of circulating miRNAs as non-invasive 
disease biomarkers is still challenging as its performance is similar to that of 
ALT or CK-18 for predicting NASH.
• miRNAs might potentially explain the association between fatty liver and 
cardiovascular disease.
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Figure 1. 
Global circulating miRNA expression profile in non-alcoholic fatty liver disease (NAFLD) 
patients and control subjects. Left, a heat map shows the results of 84 differentially 
expressed miRNAs in NAFLD patients compared with healthy controls. Red, overexpressed 
miRNAs; green, downregulated miRNAs; black, no change. The three groups of samples: 
control group, group 1 (simple steatosis) and group 2 (non-alcoholic steatohepatitis), can be 
distinguished according to the profile. Right, bars show the fold changes of significantly 
dysregulated miRNAs (p<0.05) according to disease severity.
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Figure 2. 
Validation study of selected circulating miRNAs in non-alcoholic fatty liver disease 
(NAFLD) patients and control subjects, and diagnostic accuracy in predicting histological 
disease severity. Circulating levels of miR-122, miR-192 and miR-375 are expressed 
relative to miR-23a. NASH, non-alcoholic steatohepatitis; SS, simple steatosis. The criteria 
for evaluating the severity of fatty liver infiltration, NAS and hepatocellular ballooning are 
described in the Methods Section. The receiver operating characteristic (ROC) curves with 
the corresponding area under the ROC curves for different histological features in NAFLD 
patients are shown.
Pirola et al. Page 18
Gut. Author manuscript; available in PMC 2015 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
Comparison of the diagnostic accuracy of circulating miR-122 and classic serum biomarkers 
in predicting disease severity. Receiver operating characteristic (ROC) curves with 
corresponding area under the ROC curves for comparing the ability of miR-122 and serum 
disease biomarkers, such as liver enzymes (serum alanine and aspartate aminotransferase 
(ALT and AST)) and caspase-generated CK-18 fragments, to distinguish the severity of non-
alcoholic fatty liver disease (non-alcoholic steatohepatitis and liver fibrosis) are shown.
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Figure 4. 
Analysis of circulating miR-122 in supernatant and miR-122 in argonaute2 (Ago2)-
immunoprecipitated complexes in patients with non-alcoholic fatty liver disease (NAFLD). 
(A) Measurement of circulating expression of miR-122 in serum of controls and NAFLD 
patients after immunoprecipitation of serum with Ago2 (miR-122 in supernatant/miR-122 
coimmunoprecipitated with anti-Ago2 antibody). (B) The scores on liver protein expression 
of Ago2 evaluated by immunohistochemistry with the use of a monoclonal antihuman 
antibody according to disease status. Results are expressed as mean±SE and median (range). 
The p value stands for statistical significance in a Kruskal–Wallis test. Bottom, a 
representative liver expression pattern of Ago2 evaluated by immunohistochemistry in 
patients with NAFLD and in control liver (black arrowheads show positive staining). Ago2 
immunoreactivity was examined by light microscopy of liver sections. Anti-Ago2 antibody 
immunostaining was significantly observed in the cytoplasm of hepatocytes and was 
primarily but not exclusively restricted to lipid-laden ones (inset: fat droplet, FD) and the 
edge of the wall of hepatocytes (inset) showing a granular pattern. Lobular inflammatory 
infiltrate showed negative immunoreactivity to Ago2. Counterstaining was done with 
haematoxylin. Original magnification: 400×.
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Figure 5. 
Liver expression of candidate miRNAs and localisation by in situ hybridisation (ISH). 
Right, liver expression of miR-122 (A) and miR-192 (B) in non-alcoholic fatty liver disease 
(NAFLD) patients and subjects with near-normal liver histology. Left, a representative liver 
miR-122 ISH analysis in cases and controls, showing positive staining in blue/purple and 
nuclei staining in pink. Overall, the staining was particularly localised around the lipid 
droplets (black arrows), regardless of the NAFLD histological severity, and at the edge of 
the wall of hepatocytes. Original magnification: 400×.
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Figure 6. 
In vitro exploration of the effect of miR-122 on alanine (ALT) and aspartate 
aminotransaminases (AST). Huh7 human hepatoma cells were transfected with a synthetic 
miR-122 and a miR-122 inhibitor to explore the role of miR-122 in the liver messenger 
RNA (mRNA) expression and enzymatic activity of liver transaminases. The liver 
expression of GPT1, GOT1 and GOT2 mRNA was unchanged during both miR-122 
overexpression and silencing, whereas the ALT (GPT) enzymatic activity in cell lysates 
showed a significant increase when cells were transfected with the miR-122 mimic. GPT1, 
cytosolic alanine aminotransaminase 1; GOT1, glutamic-oxaloacetic transaminase 1, 
soluble; GOT2, glutamic-oxaloacetic transaminase 2, mitochondrial.
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sk
 fa
ct
or
s
 
SA
BP
, m
m
 H
g
11
3±
12
.5
12
8.
8±
14
.5
12
9.
6±
18
<
0.
00
6
N
S
<
0.
00
8
 
D
A
BP
, m
m
 H
g
73
±8
.2
78
.2
±1
0.
3
80
.6
±1
3.
4
N
S
N
S
<
0.
05
 
C 
re
ac
tiv
e 
pr
ot
ei
n
1.
96
±2
.9
4.
2±
3.
9
3.
5±
2.
9
<
0.
04
N
S
N
S
 
Le
uc
oc
yt
e 
co
un
t (
ce
lls
/m
m3
)
71
99
±3
25
5
81
05
±2
16
9
81
07
±2
17
4
N
S
N
S
N
S
 
To
ta
l c
ho
le
ste
ro
l t
o 
(H
DL
-C
) r
ati
o
3.
74
±1
.2
4
3.
3±
1.
17
4.
43
±1
.8
N
S
N
S
N
S
 
To
ta
l c
ho
le
ste
ro
l, 
m
g/
dL
20
0±
48
.2
19
1±
47
.6
20
4.
4±
47
.4
N
S
N
S
N
S
 
H
D
L-
ch
ol
es
te
ro
l, 
m
g/
dL
58
.8
±1
4.
9
52
±1
4
48
±9
.7
N
S
N
S
<
0.
02
 
LD
L-
ch
ol
es
te
ro
l, 
m
g/
dL
11
7±
39
.7
11
7.
2±
37
.9
12
3.
1±
34
N
S
N
S
N
S
 
Tr
ig
ly
ce
rid
es
, m
g/
dL
15
2.
4±
11
2
11
3.
1±
45
.1
17
9.
8±
11
1
N
S
<
0.
02
N
S
 
U
ric
 a
ci
d,
 m
g/
dL
3.
58
±1
.4
6
5.
3±
1
5.
1±
1
<
0.
03
N
S
<
0.
04
Li
ve
r p
he
no
ty
pe
 
A
LT
, U
/L
42
.5
±2
2.
8
36
.4
±2
8.
3
61
.8
±3
7.
4
N
S
<
0.
00
04
N
S
 
A
ST
, U
/L
32
±1
4.
3
25
±1
2
46
.4
±2
2.
8
N
S
<
0.
00
00
2
<
0.
01
 
G
G
T,
 U
/L
74
.9
±7
3
56
.9
±5
0
73
.8
±1
05
N
S
N
S
N
S
 
A
P,
 U
/L
24
4.
8±
12
9
25
0±
12
7
19
9.
5±
10
8
N
S
N
S
N
S
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V
ar
ia
bl
e (
me
an
±S
D)
N
on
-M
et
Sy
n 
ne
ar
-n
or
m
al
 li
ve
r h
ist
ol
og
y 
su
bje
cts
SS
N
A
SH
p 
V
al
ue
*
p 
V
al
ue
†
p 
V
al
ue
‡
H
ist
ol
og
ic
al
 fe
at
ur
es
 
D
eg
re
e 
of
 st
ea
to
sis
, %
0.
0±
0
55
.7
±2
5.
5
55
.6
±2
3.
5
<
0.
00
00
02
<
0.
00
3
<
0.
00
04
 
Lo
bu
la
r i
nf
la
m
m
at
io
n 
(0–
3)
N
A
1.
0±
0.
56
1.
15
±0
.5
–
N
S
–
 
Po
rta
l i
nf
la
m
m
at
io
n 
(0–
2)
N
A
0.
0±
0
1.
27
±0
.7
–
<
0.
00
3
–
 
H
ep
at
oc
el
lu
la
r b
al
lo
on
in
g 
(0–
2)
N
A
0.
0±
0
0.
96
±0
.6
–
<
0.
00
00
02
–
 
Fi
br
os
is 
sta
ge
0.
0±
0
0.
0±
0
1.
45
±1
.3
<
0.
00
00
00
1
<
0.
00
00
3
<
0.
00
00
00
1
 
N
A
S
N
A
3.
1±
1.
21
5.
63
±1
.3
–
<
0.
02
–
Th
e 
to
ta
l c
ho
le
ste
ro
l t
o 
hi
gh
-d
en
sit
y 
lip
op
ro
te
in
 c
ho
le
ste
ro
l (
HD
L-
C)
 ra
tio
 w
as 
us
ed
 as
 a 
me
asu
re 
of 
CV
D 
ris
k. 
Re
su
lts
 ar
e e
xp
res
sed
 as
 m
ea
n±
SD
. *
Ind
ica
tes
 co
mp
ari
so
ns
 be
tw
ee
n S
S a
nd
 no
n-M
etS
yn
-
n
ea
r 
n
o
rm
al
 li
ve
r s
ub
jec
ts.
† S
ta
nd
s f
or
 c
om
pa
ris
on
s b
et
w
ee
n 
N
A
SH
 a
nd
 S
S.
‡ S
ta
nd
s f
or
 c
om
pa
ris
on
s b
et
w
ee
n 
N
A
SH
 a
nd
 n
on
-M
et
Sy
n-
ne
ar
 n
or
m
al
 li
ve
r. 
p 
V
al
ue
 st
an
ds
 fo
r s
ta
tis
tic
al
 si
gn
ifi
ca
nc
e 
us
in
g 
M
an
n–
W
hi
tn
ey
 U
 te
st,
 e
xc
ep
t f
or
 fe
m
al
e/
m
al
e 
pr
op
or
tio
n 
w
he
re
 p
 v
al
ue
 st
an
ds
 
fo
r s
ta
tis
tic
al
 si
gn
ifi
ca
nc
e 
us
in
g 
χ2
 
te
st
.
A
LT
 a
nd
 A
ST
, s
er
um
 a
la
ni
ne
 a
nd
 a
sp
ar
ta
te
 a
m
in
ot
ra
ns
fe
ra
se
; A
P,
 a
lk
al
in
e 
ph
os
ph
at
as
e;
 B
M
I, 
bo
dy
 m
as
s i
nd
ex
; C
V
D
, c
ar
di
ov
as
cu
la
r d
ise
as
e;
 D
A
BP
, d
ia
sto
lic
 a
rte
ria
l b
lo
od
 p
re
ss
ur
e;
 G
G
T,
 γ-
gl
ut
am
yl
-
tr
an
sf
er
as
e;
 H
O
M
A
-IR
, h
om
eo
sta
tic
 m
od
el
 a
ss
es
sm
en
t-i
ns
ul
in
 re
sis
ta
nc
e;
 L
D
L,
 lo
w
-d
en
sit
y 
lip
op
ro
te
in
; M
et
Sy
n,
 m
et
ab
ol
ic
 sy
nd
ro
m
e;
 N
A
, n
ot
 a
pp
lic
ab
le
; N
A
S,
 N
A
FL
D
 a
ct
iv
ity
 sc
or
e,
 N
A
SH
, n
on
-
al
co
ho
lic
 st
ea
to
he
pa
tit
is;
 N
S,
 n
on
-s
ig
ni
fic
an
t; 
SA
BP
, s
ys
to
lic
 a
rte
ria
l b
lo
od
 p
re
ss
ur
e;
 S
S,
 si
m
pl
e 
ste
at
os
is.
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Ta
bl
e 
4
Co
rre
la
tio
n 
be
tw
ee
n 
sig
ni
fic
an
tly
 u
pr
eg
ul
at
ed
 m
iR
N
A
s i
n 
N
A
FL
D
 p
at
ie
nt
s a
nd
 th
e 
cl
in
ic
al
 a
nd
 b
io
ch
em
ic
al
 p
ar
am
et
er
s a
nd
 fe
at
ur
es
 o
f t
he
 m
et
ab
ol
ic
 
sy
nd
ro
m
e
Sp
ea
rm
an
’s
 ra
nk
 c
or
re
la
tio
n 
te
st 
(p 
va
lue
)
 
Fe
at
ur
es
m
iR
-1
22
m
iR
-1
92
m
iR
-3
75
m
iR
-1
9a
/b
m
iR
-1
25
b
Li
ve
r p
he
no
ty
pe
-re
la
te
d 
fe
at
ur
es
 
A
LT
, U
/L
0.
4 
(0.
00
04
)
–
–
–
–
 
A
ST
, U
/L
0.
5 
(8×
10
−
4 )
0.
24
 (0
.04
)
–
–
–
 
G
G
T,
 U
/L
0.
3 
(0.
01
)
0.
24
 (0
.04
)
–
–
0.
3 
(0.
03
)
M
et
ab
ol
ic
 sy
nd
ro
m
e-
re
la
te
d 
fe
at
ur
es
 
Pl
as
m
a 
tri
gl
yc
er
id
es
, m
g/
dL
0.
32
 (0
.00
6)
0.
24
 (0
.05
)
–
–
0.
32
 (0
.03
)
 
B
M
I, 
kg
/m
2
–
–
–
0.
4 
(0.
00
04
)
0.
25
 (0
.02
)
 
Fa
st
in
g 
pl
as
m
a 
gl
uc
os
e,
 m
g/
dL
–
–
–
0.
25
 (0
.02
)
–
 
So
lu
bl
e 
in
te
rc
el
lu
la
r a
dh
es
io
n 
m
ol
ec
ul
e-
1
–
–
0.
5 
(0.
01
)
0.
4 
(0.
04
)
0.
45
 (0
.03
)
 
Pl
as
m
in
og
en
 a
ct
iv
at
or
 in
hi
bi
to
r-1
–
–
–
0.
3 
(0.
05
)
0.
3 
(0.
05
)
A
LT
 a
nd
 A
ST
, s
er
um
 a
la
ni
ne
 a
nd
 a
sp
ar
ta
te
 a
m
in
ot
ra
ns
fe
ra
se
; B
M
I, 
bo
dy
 m
as
s i
nd
ex
; G
G
T,
 γ-
gl
ut
am
yl
-tr
an
sf
er
as
e;
 N
A
FL
D
, n
on
-a
lc
oh
ol
ic
 fa
tty
 li
ve
r d
ise
as
e.
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